100
Participants
Start Date
March 22, 2021
Primary Completion Date
June 30, 2025
Study Completion Date
January 25, 2029
padeliporfin VTP
During treatment, placement at the target area of an optical light fiber, through the working channel of the ureteroscope. Intravenous administration of padeliporfin at the dose of 3.66 mg/kg infused over 10 minutes. Each target area will be illuminated for 10 minutes.
RECRUITING
Urologie und Andrologie Ordensklinikum Linz GmbH Elisabethinen, Linz
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Albany Medical College, Albany
RECRUITING
Institut Paoli-Calmettes, Marseille
RECRUITING
Hospital Universitario Reina Sofía, Córdoba
RECRUITING
Hospital Universitario de A Coruña, A Coruña
RECRUITING
The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center, Hershey
RECRUITING
The Johns Hopkins Hospital, The Sidney Kimmel Cancer Center, Baltimore
RECRUITING
Medical University of South Carolina (MUSC), Charleston
RECRUITING
Carolina Urologic Research Center, Myrtle Beach
RECRUITING
Emory University Hospital, Atlanta
RECRUITING
The Ohio State University (OSU), Columbus
RECRUITING
CHU de Lille - Hopital Claude Huriez, Lille
RECRUITING
HCL Hopital Edouard Herriot, Lyon
RECRUITING
Universitaetsklinikum Tuebingen, Tübingen
RECRUITING
University of Texas Southwestern, Dallas
RECRUITING
CHU de Rouen - Hopital Charles-Nicolle, Rouen
RECRUITING
Keck School of Medicine at USC Medical Center, Los Angeles
RECRUITING
University of California - Irvine Medical Center, Irvine
RECRUITING
University of Washington, Seattle
RECRUITING
Sheba Medical Center, Ramat Gan
RECRUITING
Hospital Universitario Vall d'Hebron, Barcelona
Collaborators (2)
PrimeVigilance
INDUSTRY
ICON plc
INDUSTRY
Steba Biotech S.A.
OTHER